EP2 inhibition restores myeloid metabolism and reverses cognitive decline
Nonsteroidal anti-inflammatory drugs alleviate pain and inflammation by inhibiting the cyclooxygenase pathway. This pathway has various downstream effects, some of which are beneficial. Prostaglandin E2 is a key downstream product in the cyclooxygenase pathway that modulates inflammation. A correlat...
Main Authors: | Ryan Lushington, MS, Samuel Camilli, Francisco Pascual, BS, Richard F. Lockey, MD, Narasaiah Kolliputi, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-05-01
|
Series: | Journal of Allergy and Clinical Immunology: Global |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829323000073 |
Similar Items
-
EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth
by: Jing-cai Niu, et al.
Published: (2019-08-01) -
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
by: Anna Semmlinger, et al.
Published: (2018-04-01) -
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
by: Yun Wang, et al.
Published: (2021-01-01) -
EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity
by: Diana I. Albu, et al.
Published: (2017-08-01) -
PGE2 inhibits neutrophil phagocytosis through the EP2R–cAMP–PTEN pathway
by: Zixuan Wang, et al.
Published: (2022-07-01)